one18

Stories

Natco Pharma has raised its proposed eGenesis investment to $16.7 million, taking its total investment in the US biotech firm to $24.7 million.
M
Moneycontrol•29-09-2026, 08:38
Natco Pharma Boosts eGenesis Investment to $16.7 Million, Total Bet Reaches $24.7 Million
  • •Natco Pharma increased its proposed investment in US-based biotechnology firm eGenesis Inc to $16.70 million from $14 million.
  • •The revised investment structure includes $13.70 million from NATCO Pharma (Canada) Inc and $3 million from NATCO Pharma USA LLC.
  • •The transaction involves cash for convertible promissory notes with an 8% annual interest rate; no additional shares are being acquired.
  • •Upon completion, expected by October 31, Natco Pharma's total investment in eGenesis will reach $24.70 million.
  • •The investment aims to support new therapeutic programs addressing critical unmet medical needs.
Read Full Article on Moneycontrol in English

Key Questions Answered

Natco Pharma increased its proposed investment in eGenesis to $16.7 million, bringing its cumulative investment to $24.7 million.

The transaction is expected to be completed by October 31, 2026.

Under the revised structure, NATCO Pharma (Canada) Inc will invest $13.7 million and NATCO Pharma USA LLC will contribute $3 million.

Similar Stories

Natco Pharma Boosts eGenesis Investment to $16.7M for Gene-Edited Organ Research

Natco Pharma Boosts eGenesis Investment to $16.7M for Gene-Edited Organ Research

C
CNBC TV18
Gland Pharma | Jefferies has a "buy" rating and a target price of 3,350 per share on the stock. It said the company's wholly-owned subsidiary Cenexi has finally turned around, achieved sustainable EBITDA breakeven and has a healthy demand outlook to deliver double-digit constant currency growth over the next three years. It said the US geography is firmly back on a growth path, supported by 3-4 differentiated product launches over the past six months. Jefferies expects the ramp-up of newly-launched products and an expanding complex product portfolio to drive a high-teens CAGR in the region. It said the management's guidance of 20% total sales growth over the next four years is significantly higher than consensus estimates of mid-teens growth and leaves room for consistent earnings upgrade. It values the stock at 32x September 2028 EPS estimates and it assigns high multiple on significantly higher sales/EBITDA growth and stronger execution in recent few quarters.

Gland Pharma Invests $21 Million in US Drugmaker, Acquires 60% Stake in Novelstar Pharma

C
CNBC TV18
Natco Pharma Launches Carboplatin Injection in US Market, Shares Rise 2%

Natco Pharma Launches Carboplatin Injection in US Market, Shares Rise 2%

C
CNBC TV18
Schneider Electric to Acquire PTC for $22.6 Billion in Historic Deal

Schneider Electric to Acquire PTC for $22.6 Billion in Historic Deal

C
CNBC TV18
Skillmatics CEO and founder Dhvanil Sheth. Edited via ChatGPT

Skillmatics Nears $75 Million Funding Round from Premji Invest, ChrysCapital, A91 Partners

M
Moneycontrol
Nava builds private cloud infrastructure for enterprises by offering a secure and scalable stack in the AI era.

Nava, AI Data Centre Startup, Seeks $200 Million from Greenoaks in Major Fundraise

M
Moneycontrol